CN Patent

CN114096544B — Kras g12c抑制剂及其用途

Assigned to California Institute of Technology · Expires 2025-08-12 · 1y expired

What this patent protects

本发明涉及式I化合物及其药学上可接受的盐、其制备方法及其用途。本发明的化合物对抑制具有G12C突变的KRAS蛋白有效，且适合于在治疗完全或部分地由KRAS G12C突变介导的癌症的方法中使用。

USPTO Abstract

本发明涉及式I化合物及其药学上可接受的盐、其制备方法及其用途。本发明的化合物对抑制具有G12C突变的KRAS蛋白有效，且适合于在治疗完全或部分地由KRAS G12C突变介导的癌症的方法中使用。

Drugs covered by this patent

Patent Metadata

Patent number: CN114096544B
Jurisdiction: CN
Classification: —
Expires: 2025-08-12
Drug substance claim: No
Drug product claim: No
Assignee: California Institute of Technology
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.